MCA
ROIV icon

Maryland Capital Advisors’s Roivant Sciences ROIV Stock Holding History

Maryland Capital Advisors’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$177 Buy
+5
New +$148 ﹤0.01% 489

Other funds holding ROIV

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
QF
QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Maryland Capital Advisors's ROIV Position: Q2 2026 in Review

Maryland Capital Advisors opened a new position in Roivant Sciences (ROIV) in Q2 2026: 5 shares worth $177. The stake represents ﹤0.01% of the portfolio and ranks #489 among its holdings.

498 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

  • Maryland Capital Advisors held 5 shares of Roivant Sciences worth $177 as of Q2 2026.
  • Roivant Sciences was a new Maryland Capital Advisors position in Q2 2026.
  • Roivant Sciences made up ﹤0.01% of Maryland Capital Advisors's portfolio in Q2 2026, its #489 holding.
  • 498 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Maryland Capital Advisors's 13F filing for Q2 2026, filed 17 Jul 2026.